News

The trial involved 90 healthy male and female volunteers. Doses originally intended for study ranged from 1mg to 160mg, but due to excellent tolerability the maximum dose was

Thomas Hall, NovaMed’s chairman, president and CEO, said: “With over $24 million in gross sales and approximately $2.4 million in net revenue, The Buying Group represented an attractive

The collaboration between Oncology Metrics’s sample procurement network Cure Pace and Cureline is expected to improve the access of industrial and academic researchers to high-quality biospecimens. Olga Potapova,

The restructured agreement eliminates all milestone payments and reduces royalties owed to Genzyme to single digits. In return for the reduced future payments to Genzyme, Callisto is paying

As part of the agreement, Cilag International will pay upfront and milestone payments up to $39 million as well as ongoing royalties on commercial sales of Vivitrol in

The Phase III safety study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular events driven study of between 2,400 and 3,100 women exposed to LibiGel or placebo for 12

Under the terms of the agreement, Eucalyptus has acquired worldwide exclusive rights to develop and commercialize the molecule and Yissum together with Ramot, the technology transfer company of

The Phase II trial for NKTR-118 is a multi-center, placebo-controlled, dose-escalation trial (5mg, 25mg, 50mg or 100mg) that will evaluate the efficacy, safety and tolerability of NKTR-118 in

AMG 623, which has completed Phase Ib studies in systemic lupus erythematosus patients, is a peptide fusion protein that binds to B-cell activating factor (BAFF). Anthera anticipates initiating